Skip to main content
NIH funding notice RFA-DK-21-031

Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed)

Closed on October 26, 2022.

Posted
July 14, 2022
Close date
October 26, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
2
2 new
Median first-year cost
$925,148
$1,850,296 in all
Institutions
2
2 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. BATTELLE PACIFIC NORTHWEST LABORATORIES1
  2. UNIVERSITY OF WASHINGTON1

Most frequent study sections

  1. Special Emphasis Panel (ZDK1 GRB-9 (M2))2
2 awards under RFA-DK-21-031 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2023Robust Mass Spectrometric Protein/Peptide Assays for Type 1 Diabetes Clinical Applications1U01DK137113-01Qian, Wei-JunQu, JunBATTELLE PACIFIC NORTHWEST LABORATORIES, WAFirst-year cost $982,617Study section ZDK1
FY2023Quantifying proteins in plasma do democratize personalized medicine for patients with type 1 diabetes1U01DK137097-01Hoofnagle, Andrew NMaccoss, MichaelUNIVERSITY OF WASHINGTON, WAFirst-year cost $867,679Study section ZDK1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-14-0.3.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.